Aspire Biopharma Holdings, Inc. 10-Q

ITEM 5. OTHER INFORMATION None. ​ ​ 28 Table of Contents ITEM 6. EXHIBITS The following exhibits are filed as part of, or incorporated by reference into, this Quarterly Report on Form 10-Q. ​ Exhibit No. Description 31.1* ​ Certification of Principal Executive Officer Pursuant to Securities Exchange Act Rules 13a-14(a) and 15(d)-14(a), as adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 31.2* ​ Certification of Principal Financial Officer Pursuant to Securities Exchange Act Rules 13a-14(a) and 15(d)-14(a), as adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 32.1** ​ Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 32.2** ​ Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 101.INS* ​ Inline XBRL Instance Document 101.CAL* ​ Inline XBRL Taxonomy Extension Calculation Linkbase Document 101.SCH* ​ Inline XBRL Taxonomy Extension Schema Document 101.DEF* ​ Inline XBRL Taxonomy Extension Definition Linkbase Document 101.LAB* ​ Inline XBRL Taxonomy Extension Labels Linkbase Document 101.PRE* ​ Inline XBRL Taxonomy Extension Presentation Linkbase Document 104 ​ Cover Page Interactive Data File (formatted in Inline XBRL and included as Exhibit 101) * Filed herewith. ** Furnished herewith. ​ ​ ​ 29 Table of Contents SIGNATURES In accordance with the requirements of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. ​ ​ ​ ​ ​ POWERUP ACQUISITION CORP. ​ ​ ​ Date: November 10, 2022 By: /s/ Jack Tretton ​ Name: Jack Tretton ​ Title: Chief Executive Officer, Director ​ ​ (Principal Executive Officer) ​ ​ ​ ​ Date: November 10, 2022 By: /s/ Michael Olson ​ Name: Michael Olson ​ Title: Chief Financial Officer ​ ​ (Principal Financial and Accounting Officer) ​ ​ ​ ​ 30